11.2.Sotorasib indications published in EMA Data Sheet not funded by SNS in Spain:EMA #1 indication: Sotorasib monotherapy is indicated for treatment of adults with advanced NSCLC with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy [73].Clinical evidence approval EMA indication #1: Phase I/II CodeBreak100 (NCT03600883) clinical trial in patients with advanced NSCLC KRAS G12C mutation who had progressed after at least one prior treatment. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.